Christian Schuetz

Christian Schuetz

Auto-generated profile, based on publicly available information

Christian Schuetz

Transplant Surgery Division, Massachusetts General Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2010 in Nature Medicine
Verified
Journal Article
Closed access
HOHarald C Ott
Harald C Ott
BCBen Clippinger
Ben Clippinger
CCClaudius Conrad
Claudius Conrad
CSChristian Schuetz
Christian Schuetz
IPIrina Pomerantseva
Irina Pomerantseva
JVJoseph P Vacanti
Joseph P Vacanti

26 February 2012 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
BBBarak Blum
Barak Blum
SHSiniša Hrvatin
Siniša Hrvatin
CSChristian Schuetz
Christian Schuetz
CBClaire Bonal
Claire Bonal
ARAlireza Rezania
Alireza Rezania
DMDouglas A Melton
Douglas A Melton

15 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MNMoufida Ben Nasr
Moufida Ben Nasr
STSara Tezza
Sara Tezza
FDFrancesca D'Addio
Francesca D'Addio
CMChiara Mameli
Chiara Mameli
VUVera Usuelli
Vera Usuelli
Paolo FiorinaPaolo Fiorina
Paolo Fiorina
Restoration of a PD-L1 defect in HSPCs reverses diabetes in NOD mice and thus may represent a potential cure for T1D.

1 September 2005 in Journal of Neurotrauma
Verified
Journal Article
Closed access
DEDana L. Emery
Dana L. Emery
CFCarl T. Fulp
Carl T. Fulp
KSKathryn E. Saatman
Kathryn E. Saatman
CSChristian Schütz
Christian Schütz
ENEdmund Neugebauer
Edmund Neugebauer
TMTracy K. McIntosh
Tracy K. McIntosh
We investigated whether new neurons generated in the adult rat brain following lateral fluid percussion traumatic brain injury (TBI) are capable of projecting axons along the mossy fiber pathway to the CA3 region of the hippocampus. Dividing cells were labeled by intraperitoneal injection of bromodeoxyuridine (BrdU) on the day of surgery/injury, and neurons that extended axons to the CA3 region were retrogradely labeled by fluorescent tracers (FluoSpheres), stereotactically injected into the CA3 region of both the ipsi- and contralateral hippocampus at 1 or 12 days following TBI (n = 12) or sham injury (n = 12) in anaesthetized rats. Animals (n = 6 injured and n = 6 sham-injured controls per time point) were sacrificed at either 3 or 14 days post-injury. Another group of animals (n = 3) was subjected to experimental TBI and BrdU administration and sacrificed 3 days after TBI to be processed for BrdU and immunohistochemistry for polysialylated neural cell adhesion molecule (PSA-NCAM), a growth-related protein normally observed during CNS development. A fivefold bilateral increase in the number of mitotically active (BrdU+) cells was noted within the dentate gyrus when compared to uninjured controls as early as 3 days following TBI. A subgroup of dividing cells was also immunoreactive for PSA-NCAM at 3 days following TBI. By 2 weeks post-injury the number of BrdU+ cells within the dentate gyrus was increased twofold compared to the uninjured counterparts and a proportion of these newly generated cells showed cytoplasmic staining for the fluorescent tracer. These findings document rapid neurogenesis following TBI and show, for the first time, that newly generated granule neurons are capable of extending projections along the hippocampal mossy fiber pathway in the acute post-traumatic period.

1 September 2010 in Diabetes
Verified
Journal Article
Open access
AVAndrea Vergani
Andrea Vergani
FDFrancesca D'Addio
Francesca D'Addio
MJMollie Jurewicz
Mollie Jurewicz
APAlessandra Petrelli
Alessandra Petrelli
TWToshihiko Watanabe
Toshihiko Watanabe
Paolo FiorinaPaolo Fiorina
Paolo Fiorina
OBJECTIVE: To investigate a new clinically relevant immunoregulatory strategy based on treatment with murine Thymoglobulin mATG Genzyme and CTLA4-Ig in NOD mice to prevent allo- and autoimmune activation using a stringent model of islet transplantation and diabetes reversal.RESEARCH DESIGN AND METHODS: Using allogeneic islet transplantation models as well as NOD mice with recent onset type 1 diabetes, we addressed the therapeutic efficacy and immunomodulatory mechanisms associated with a new immunoregulatory protocol based on prolonged low-dose mATG plus CTLA4-Ig.RESULTS: BALB/c islets transplanted into hyperglycemic NOD mice under prolonged mATG+CTLA4-Ig treatment showed a pronounced delay in allograft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P < 0.0001). Immunologic analysis of mice receiving transplants revealed a complete abrogation of autoimmune responses and severe downregulation of alloimmunity in response to treatment. The striking effect on autoimmunity was confirmed by 100% diabetes reversal in newly hyperglycemic NOD mice and 100% indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice).CONCLUSIONS: The capacity to regulate alloimmunity and to abrogate the autoimmune response in NOD mice in different settings confirmed that prolonged mATG+CTLA4-Ig treatment is a clinically relevant strategy to translate to humans with type 1 diabetes.

1 July 2012 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
KKKaren Kim
Karen Kim
CSChristian Schuetz
Christian Schuetz
NENahel Elias
Nahel Elias
GVGregory R. Veillette
Gregory R. Veillette
IWIsaac Wamala
Isaac Wamala
MHMartin Hertl
Martin Hertl